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Recent success in monoclonal antibody based immuno-oncology therapeutics such as Keytruda® has initiated a 
revolution within the Biopharmaceutical Industry.  Development efforts to support this class of molecules include 
single-use technology, continuous production, process analytical technology (PAT), information technology (IT), 
multivariate data analysis (MVDA), and efforts towards real time release testing (RTRT).  Merck’s vision for a 
next-generation large molecule production facility aligns with these six key principles, as demonstrated by the 
construction of a continuous monoclonal antibody (mAb) production pilot plant named the Protein Refinery 
Operations lab (PROLab) within Merck Bioprocess Development.   
 
Quality-by-Design (QbD) principles are maturing for the development of standard batch-based therapeutic 
protein manufacturing processes.  Outside of the insight gained through similar techniques applied to unit 
operations run in a continuous mode, similar approaches for the dependencies created by connected and 
continuous processes are still in their infancy.  Previously, a methodology for characterizing holistic downstream 
process performance through real time perturbation analysis, where the response to an upstream stimulus is 
monitored at several unit operations simultaneously was presented to start applying QbD principles to 
continuous bioprocessing.   
 
Here, the authors build upon the concept of perturbation analysis by presenting case studies where advanced 
PAT tools have been embedded in PROLab operation.  At-line and off-line process and product quality data 
from continuous upstream and downstream production will be presented over the course of long term perfusion 
cell culture with variable production rates.  Specific emphasis will be placed on the performance of bioreactor 
cell retention and clarification trains, and post-chromatographic ultrafiltration unit operations.  This process 
understanding can then be utilized to place PAT tools at the appropriate locations in the process to achieve 
product attribute control and ultimately to assure uninterrupted supply of therapeutic proteins to patients. 
